Bio-Rad
Bio-Rad Laboratories Q2 Revenues Climb 33 Percent, Beat Estimates
The firm saw growth across both its life science and clinical diagnostics businesses due to gradual recovery from the pandemic and increased its guidance for 2021.
Bio-Rad Laboratories Gets CE Mark for SARS-CoV-2, Influenza RT-PCR Assay Kit
The kit simultaneously detects the N gene of SARS-CoV-2 as well as influenza A and B targets in a single reaction.
FDA Grants EUAs for SARS-CoV-2 Tests, Kits From Exact Sciences, BioGx, Bio-Rad, Everlywell
Exact and BioGx's tests are molecular, while Bio-Rad's is a serology test. Everlywell received its EUA for a nasal specimen self-collection kit.
Bio-Rad Laboratories, Seegene Partner for Infectious Disease MDx Development
The firms will develop and commercialize multiplex RT-PCR assays to detect infectious diseases for the US market.
Bio-Rad Laboratories Gets CE Mark for SARS-CoV-2 Kit
The assay kit detects two regions of the N gene and is validated on Bio-Rad's CFX96 Dx as well as other RT-PCR instruments.
Apr 29, 2021
Bio-Rad Q1 Revenues Rise 27 Percent, Beat Estimates
Feb 12, 2021
Oct 29, 2020
Bio-Rad Q3 Revenues Jump 15 Percent
May 6, 2020